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Abstract
Introduction: Diffuse lung infiltrates are a common finding in patients with acquired immunodeficiency syndrome
and causes range from infectious processes to malignancies or interstitial lung diseases. Pulmonary alveolar
proteinosis is a rare pulmonary disorder rarely reported in patients infected with human immunodeficiency virus.
Secondary pulmonary alveolar proteinosis is associated with conditions involving functional impairment or reduced
numbers of alveolar macrophages. It can be caused by hematologic malignancies, inhalation of toxic dust, fumes
or gases, infectious or pharmacologic immunosuppression, or lysinuric protein intolerance.
Case presentation: A 42-year-old African American man infected with human immunodeficiency virus was
admitted with chronic respiratory symptoms and diffuse pulmonary infiltrates. Chest computed tomography
revealed bilateral spontaneous pneumothoraces, for which he required bilateral chest tubes. Initial laboratory
investigations did not reveal any contributory conditions. Histological examination of a lung biopsy taken during
video-assisted thoracoscopy showed pulmonary alveolar proteinosis concurrent with cytomegalovirus pneumonitis.
After ganciclovir treatment, our patient showed radiologic and clinical improvement.
Conclusion: The differential diagnosis for patients with immunosuppression and lung infiltrates requires extensive
investigations. As pulmonary alveolar proteinosis is rare, the diagnosis can be easily missed. Our case highlights the
importance of invasive investigations and histology in the management of patients infected with human
immunodeficiency virus and pulmonary disease who do not respond to empiric therapy.
Introduction
Pulmonary alveolar proteinosis (PAP) was first described
in 1958 by Rosen et al. [1]. It is a rare pulmonary disor-
der characterized by an abnormal accumulation of sur-
factant-derived material in the alveoli, leading to disease
that ranges from mild symptoms with complete sponta-
neous resolution to progressive disease with ensuing
respiratory failure [1,2].
Associated infections have been reported in 5 to 20% of
PAP cases. This wide range may be due to reporting bias
or difficulties detecting infectious processes [3]. The infec-
tious agents include Nocardia asteroides, Mycobacterium
tuberculosis, Mycobacterium avium-intracellulare, Pneu-
mocystis jirovecii (formerly carinii) and cytomegalovirus
(CMV). Most of these infectious agents have been
reported in immunocompromised patients uninfected
with human immunodeficiency virus (HIV); however, PAP
is a rare finding in patients with HIV [4].
Case presentation
We present a unusual case of a patient with HIV infec-
tion admitted with chronic respiratory symptoms, dif-
fuse pulmonary infiltrates and bilateral spontaneous
pneumothoraces, who was found to have PAP concur-
rent with Cytomegalovirus pneumonitis. Our patient was
a 42-year-old African-American man, who was admitted
with fever, productive cough with whitish sputum, fati-
gue, and weight loss of 6.8 kg in the previous month.
He reported no visual abnormalities, and denied travel-
ing or relevant any medical or surgical history.
Our patient performed maintenance work, and
smoked 20 packs of cigarettes per year, but denied
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tuberculosis (purified protein derivative) in the previous
year, which was negative.
On physical examination, our patient was found to be
febrile, tachycardic and tachypneic. His lungs were clear
on auscultation, and the rest of the examination was nor-
mal. Arterial blood gas analysis revealed PaO2 of 79 mm
Hg (80-100 mmHg normal range at ambient air) and
SaO2 o f9 3 %i n2Lo fo x y g e n( n o r m a lv a l u e sa r e9 7 %t o
99% at ambient air). Initial laboratory test results showed
elevated lactate dehydrogenase (LDH) of 528 U/L, nor-
mal liver and kidney function, and packed cell volume of
32%. Results for HIV testing were positive, with a CD4+
T-cell count of 12 cells/μL. Chest radiography showed a
bilateral interstitial pattern (Figure 1). Chest computed
tomography (CT) revealed bilateral pneumothoraces,
multiple pneumatoceles, and bilateral consolidation with
ground-glass opacity (GGO) (Figure 2).
Because of progressive dyspnea, our patient was trans-
ferred to the intensive care unit 24 hours after admis-
sion, where he underwent bilateral chest tube insertion.
The initial differential diagnosis was community-
acquired pneumonia or an opportunistic infection, typi-
cally Pneumocystis in a patient infected with HIV. Pneu-
mothoraces and elevated LDH supported the diagnosis
of Pneumocystis pneumonia (PCP), therefore antibiotics
(ceftriaxone, azithromycin, trimethoprim-sulfamethoxa-
zole) and corticosteroids were initiated. Sputum studies
for PCP, acid-fast bacilli (AFB) and influenza were nega-
tive, as were blood and urine cultures. Our patient
refused fiberoptic bronchoscopy.
Our patient’s condition continued to deteriorate despite
treatment. On the third day after admission, he required
noninvasive positive pressure ventilation (fraction of
inspired oxygen was 50%) to maintain O2 saturation at
92%. Because of a persistent air leak, two chest tubes were
required in each lung, and on day six after admission, our
patient underwent bilateral sequential video-assisted
thoracoscopic surgery and lung biopsy. Histological exami-
nation of the biopsy revealed foamy macrophages, and
PAS-positive, diastase-resistant and mucicarmine-negative
material. Pneumocystis organisms were not detected by
direct immunofluorescence with monoclonal antibodies.
Histopathology revealed CMV inclusion bodies and pro-
teinaceous material filling the alveoli.
On day 10 after admission, ganciclovir was started,
and the other antibiotics were discontinued (Figure 3,
Figure 4). Results of serology testing for CMV were
positive, and ophthalmology evaluation for CMV
Figure 1 Chest radiograph showing bilateral interstitial-alveolar
pattern.
Figure 2 Chest computed tomography scan showing bilateral
pneumothoraces, several pneumatoceles, bilateral airspace
consolidation, and ground-glass opacity.
Figure 3 Lung biopsy showing proteinaceous material filling
the alveoli. Magnification × 200.
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radiologic improvement, and he was discharged 46 days
after admission (Figure 5).
Discussion
Epidemiological data regarding the incidence and preva-
lence of PAP have been gathered from small case series
and single case reports. The incidence of PAP is
reported to be 0.36 to 0.49 cases per million in the
population, with a prevalence of 3.70 to 6.2 cases per
million. PAP occurs in all age groups, but is most com-
mon in men (male:female ratio 3:1) and among people
aged 20 to 50 years. PAP is three times as common in
smokers than in non-smokers, and in North America,
72% of patients with PAP are smokers [2,4].
There are three clinically distinct forms of PAP: con-
genital (2% of cases), acquired (also referred as primary
or idiopathic, 90%), and secondary (5 to10%) [2].Conge-
nital PAP is a heterogeneous collection of disorders
caused by homozygous mutation of the genes encoding
surfactant proteins (SP)-B and SP-C and the ABCA3
(ATP-binding cassette, sub-family A, member 3) trans-
porter, or by the absence of the granulocyte macrophage
colony-stimulating factor (GM-CSF) receptor [3,5]. Pri-
mary PAP is regarded as an autoimmune condition. It is
characterized by excess surfactant caused by GM-CSF-
neutralizing antibodies, receptor deficiency or gene defi-
ciency/mutation, which leads to decreased macrophage
stimulation. As a result, the immature alveolar macro-
phages are incapable of proper surfactant clearance
[4-6]. Secondary PAP is uncommon, and develops in
association with conditions involving functional impair-
ment or reduced numbers of alveolar macrophages. It is
caused by hematologic malignancies, inhalation of toxic
dust, fumes or gases, infectious or pharmacologic immu-
nosuppression, and lysinuric protein intolerance.
Patients infected with HIV have altered immunity
and are susceptible to opportunistic lung infections.
The subsequent breakdown of the alveolar lining, over-
production of substances normally secreted into the
alveoli, impairment of alveolar clearance, and the trans-
udation of plasma constituents into the alveoli may con-
tribute to the pathogenesis of PAP [7]. Despite these
risk factors, few reports exist of PAP in patients infected
with HIV, and those cases of PAP that have been
reported have been primarily associated with P. jirovecii,
mycobacteria. or rarely, CMV infections [7-10].
The clinical presentation of PAP varies from asympto-
matic (31% of acquired cases) to a more chronic presen-
tation with dyspnea (39%), dyspnea and cough (11%), or
cough only (10%). Cough is usually nonproductive, but
is sometimes accompanied by sputum described as
‘white and gummy’ or ‘chunky’. Fever and weight loss
can also occur.
The physical examination is typically nonspecific:
crackles, clubbing and cyanosis all have been reported,
but rarely [11]. The radiographic findings are nonspeci-
fic, with chest radiography typically showing bilateral
central and symmetric lung opacities with relative spar-
ing of the apices and costophrenic angles, and less com-
monly, multifocal asymmetric opacities. Extensive
diffuse consolidations have also been reported, suggest-
ing interstitial pulmonary edema. Lymphadenopathy is
rarely present. Chest CT findings are nonspecific and
show smooth thickening of septal lines superimposed on
areas of GGO, known as ‘crazy paving’. A high-resolution
Figure 4 Lung biopsy showing cytomegalovirus inclusion body
(arrow) in a background of proteinaceous material filling the
alveoli. Magnification × 400.
Figure 5 Chest radiograph at discharge showing improvement
in infiltrates.
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more diffuse than autoimmune PAP. Pneumothoraces
associated with PAP have been rarely reported, usually in
association with PCP. In addition, a report suggests that
emphysematous bullae in patients with PAP could lead
to pneumothoraces [12-14].
Abnormal nonspecific laboratory findings in PAP
include increased levels of serum LDH and other pro-
tein products of pulmonary epithelial cells such as carci-
noembryonic antigen, cytokeratin 19, KL-6 mucin, SP-A,
SP-B and SP-D [2]. GM-CSF auto-antibodies are ele-
vated in primary PAP, but normal in secondary and
congenital PAP [2,4]. Pulmonary function test usually
reveals restrictive lung disease, decreased carbon mon-
oxide diffusing capacity, increased alveolar-arterial par-
tial oxygen pressure (PO2) gradient, hypoxemia and
elevated shunt fraction.
The gold standard for PAP diagnosis is open lung
biopsy, but fiberoptic bronchoscopy can diagnose up to
75% of PAP cases. Bronchoalveolar lavage and trans-
bronchial biopsy are usually performed to exclude infec-
tion. The classic findings include a ‘milky’ fluid
containing large amounts of granular acellular eosino-
philic proteinaceous material, with morphologically
abnormal ‘foamy’ macrophages engorged with diastase-
resistant PAS-positive intracellular inclusions. Mucicar-
mine and PCP stains are negative, as in our case. When
electron microscopy is available, the presence of concen-
trically laminated phospholipid structures called lamellar
bodies can confirm the diagnosis [6,11,15]. Lung lavage
fluid samples generally do not contain microbes, and it
is now known that most cases of encountered infection
are a secondary event rather than the initiating process
[2].
Treatment of PAP depends on the physiologic impair-
ment, rate of progression or remission and the underly-
ing pathology. Supportive treatment and occasional lung
transplantation are used for congenital PAP. Secondary
PAP is managed with conservative therapy and treat-
ment of the associated condition. In primary PAP, the
standard of care is whole-lung lavage performed under
general anesthesia. GM-CSF replacement is still experi-
mental. The appropriateness of whole-lung lavage for
secondary PAP with severe respiratory impairment is
unclear at the present time [2,3,11].
Conclusion
In conclusion, the differential diagnosis of diffuse lung
infiltrates in patients with acquired immunodeficiency
syndrome requires extensive investigation, as causes
range from infectious processes to malignancies or
interstitial lung diseases. Pneumothoraces in patients
with HIV infection are usually attributed to PCP infec-
tion or emphysema caused by tobacco use or by the
HIV infection itself. PAP is rare in these patients, thus it
can easily be misdiagnosed. Clinicians caring for patients
infected with HIV must consider PAP, either alone or in
combination with CMV or other opportunistic infection,
during the differential diagnosis. Tissued i a g n o s i si s
important, as is careful histological examination of
bronchoscopic lavage fluid and biopsies. A surgical lung
biopsy should be considered in cases of infiltrates of
unclear etiology or progressive clinical deterioration
despite treatment.
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